GlassScriptPhysician profile
Ian B Ross
NPI 1003853730
$3,846.30
in general payments reported to CMS, 2019-2025
31 companies · $814 in 2025
The $814 reported for 2025 was more than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $371 · 2020: $30.15 · 2021: $358 · 2022: $252 · 2023: $927 · 2024: $1,094 · 2025: $814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,834.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,823.99 | 2021-2025 | Solitaire X, Pipeline, Axium Primetm |
| Boston Scientific Corporation | $321.19 | 2024-2025 | General - Dbs |
| Medtronic USA, INC. | $307.21 | 2019-2020 | |
| Depuy Synthes Sales INC. | $232.09 | 2019-2024 | Trufill |
| Abbott Laboratories | $179.12 | 2023-2025 | Infinity, Proclaim |
| Stryker Corporation | $154.69 | 2021-2024 | Mild Device Kit |
| Imperative Care, INC | $139.00 | 2023-2024 | Zoom Reperfusion Catheter, Zoom 88-T Large Distal Platform |
| Livanova USA, INC. | $88.68 | 2019-2022 | |
| Microtransponder, INC. | $46.06 | 2025 | |
| Abbvie INC. | $43.20 | 2025 | |
| Alphatec Spine, INC | $43.02 | 2024 | Invictus Open |
| Ucb, INC. | $38.10 | 2025 | Nayzilam |
| Globus Medical, INC. | $37.49 | 2023 | Excelsiusgps Robotic Navigation System |
| Sk Life Science, INC. | $34.96 | 2025 | |
| Nevro Corp. | $33.46 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $31.69 | 2025 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $30.87 | 2025 | Austedo Xr |
| Lilly USA, LLC | $30.12 | 2025 | Kisunla |
| Lemaitre Vascular, INC. | $29.42 | 2025 | Anastoclip Gc 8cm (Medium) |
| Argenx US, INC. | $28.52 | 2025 | Vyvgart Hytrulo |
| Biogen, INC. | $24.31 | 2025 | Spinraza |
| Janssen Biotech, INC. | $24.13 | 2025 | |
| Xeris Pharmaceuticals, INC. | $23.21 | 2025 | Keveyis |
| Vanda Pharmaceuticals INC. | $21.87 | 2019 | |
| Monteris Medical Corporation | $20.22 | 2024 | Neuroblate |
| Arbor Pharmaceuticals, INC. | $17.45 | 2019 | |
| Genzyme Corporation | $16.23 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $14.00 | 2023 | Andexxa |
| Arteriocyte Medical Systems, INC. | $12.00 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$112,743.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ian Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.